Home › NDC Lookup › Ingredients › Irbesartan › 53360-1307-00
⚪image loading
(from DailyMed)

Irbesartan 300 mg Tablet, Film Coated, 46,153-count — NDC 53360-1307-0 (Billing 53360-1307-00)

by Sanofi Winthrop Industrie · 46153 TABLET, FILM COATED in 1 DRUM

This is a package of 46,153 tablets of Irbesartan 300 mg Tablet, Film Coated from Sanofi Winthrop Industrie, marketed since Feb 2012 and currently FDA-listed. It is this product's only package size.

NDC 53360-1307-00
🏷️ FDA NDC (as labeled) 53360-1307-0 billing pads the package segment with a zero
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 53360-1307-0
Product NDC 53360-1307
11-digit billing NDC 53360130700
SPL Set ID f29705e1-eb1c-4b71-e053-2a95a90a9493
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2012-02-27
Dosage form TABLET, FILM COATED
Substance IRBESARTAN
Why two NDCs? The FDA registers this code as 53360-1307-0 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 53360-1307-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

📗 Our plain-language guide HelloPharmacist
  • Irbesartan lowers high blood pressure, which helps reduce your risk of stroke and heart attack. It is also used to slow kidney damage in people with type 2 diabetes, high blood pre...
  • Take it by mouth once a day, with or without food. Following your prescriber's directions and the pharmacy label is important. Try to take it at the same time each day.
  • Some people feel tired, get diarrhea or heartburn, or feel dizzy, especially when standing up quickly. Call your doctor if dizziness is severe or you faint. Get emergency help for...
  • No. Irbesartan can seriously harm or even kill a developing baby, especially in the second and third trimesters. If you become pregnant or think you might be, call your doctor righ...
📖 Read our full Irbesartan guide →
1
Nutrient depletion considerations

Irbesartan may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Irbesartan nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
53360-1307-00 You're viewing this Main listing 46153 TABLET, FILM COATED in 1 DRUM — — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Irbesartan 300 mg 50268-0442-15 AvPAK 50 tablets $0.156 AB Discontinued —
Irbesartan 300 mg 62332-0043-30 Alembic 30 tablets $0.162 AB Availability likely —
Irbesartan 300 mg 72603-0672-01 NorthStar 30 tablets $0.162 AB Availability likely —
Irbesartan 300 mg 31722-0731-05 Camber 500 tablets $0.162 AB Availability likely —
Irbesartan 300 mg 43547-0376-03 Solco 30 tablets $0.162 AB Availability likely —
Irbesartan 300 mg 33342-0049-07 Macleods 30 tablets $0.162 AB Availability likely —
Avapro 300 mg 00024-5852-30 Sanofi-Aventis 30 tablets $8.792 AB Availability likely —
Irbesartan 300 mg 31722-0162-05 Camber 500 tablets — AB FDA listed —
Irbesartan 300 mg 50228-0162-05 ScieGen 500 tablets — AB FDA listed —
Irbesartan 300 mg 46708-0441-30 Alembic 30 tablets — AB FDA listed —
Irbesartan 300 mg 50090-2017-00 A-S 30 tablets — AB FDA listed —
Irbesartan 300 mg 50090-6938-00 A-S 90 tablets — AB FDA listed —
Irbesartan 300 mg 68180-0412-02 Lupin 500 tablets — — FDA listed —
Irbesartan 300 mg 71335-0071-01 Bryant 30 tablets — AB FDA listed —
Irbesartan 300 mg 63629-5241-01 Bryant 30 tablets — AB FDA listed —
Irbesartan 300 mg 70518-2246-00 REMEDYREPACK 90 tablets — AB FDA listed —
Irbesartan 300 mg 72205-0329-05 Novadoz 500 tablets — AB FDA listed —
Irbesartan 300 mg 59746-0449-05 Jubilant 500 tablets — AB FDA listed —
Irbesartan 300 mg 29300-0214-05 Unichem 500 tablets — AB FDA listed —
Irbesartan 300 mg 65862-0639-05 Aurobindo 500 tablets — — FDA listed —
Irbesartan 300 mg 70518-1543-01 REMEDYREPACK 90 tablets — AB FDA listed —
Irbesartan 300 mgthis 53360-1307-00 Sanofi 46153 tablets — — FDA listed —
Irbesartan 300 mg 50090-2978-00 A-S 30 tablets — AB FDA listed —
Irbesartan 300 mg 50090-7622-00 A-S 90 tablets — AB FDA listed —
Irbesartan 300 mg 62135-0978-30 Chartwell 30 tablets — AB FDA listed —
Irbesartan 300 mg 71335-1826-01 Bryant 30 tablets — AB FDA listed —
Irbesartan 300 mg 72189-0270-90 direct 90 tablets — AB FDA listed —
Irbesartan 300 mg 42291-0942-90 AvKARE 90 tablets — AB FDA listed —
Irbesartan 300 mg 42658-0123-01 Hisun 30 tablets — AB FDA listed —
Irbesartan 300 mg 65162-0286-03 Amneal 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2012
On the market since
Feb 2012
📍
2026
Currently FDA-listed
14 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSanofi Winthrop Industrie
Labeler code53360
First marketedFeb 2012
Product typeDrug For Further Processing
Portfolio30 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Irbesartan (matched by generic name) — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Irbesartan. CMS lists 2 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$12.61M
Claims incl. refills
647.9K
Beneficiaries
530.1K
Spend / beneficiary
$23.80
Spend / claim
$19.47
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Sanofi Winthrop Industrie supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Sanofi Winthrop Industrie. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Sanofi Winthrop Industrie is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 53360-1305-00 · Sanofi 53360-1309-00 · Sanofi →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.